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Drug-induced parkinsonism is the second most common cause of parkinsonism after Parkinson's disease
and their distinction has crucial implications in terms of management and prognosis. However, differ-
entiating between these conditions can be challenging on a clinical ground, especially in the early stages.
We therefore performed a review to ascertain whether assessment of non-motor symptoms, or use of
ancillary investigations, namely dopamine transporter imaging, transcranial sonography of the sub-
stantia nigra, and scintigraphy for myocardial sympathetic innervation, can be recommended to
distinguish between these conditions.
Among non-motor symptoms, there is evidence that hyposmia can differentiate between patients with
“pure” drug-induced parkinsonism and those with degenerative parkinsonism unmasked by an anti-
dopaminergic drug. However, several issues, including smoking history and cognitive functions, can
inﬂuence smell function assessment. Higher diagnostic accuracy has been demonstrated for dopamine
transporter imaging. Finally, preliminary evidence exists for sympathetic cardiac scintigraphy to predict
dopaminergic pathway abnormalities and to differentiate between drug-induced parkinsonism and
Parkinson's disease.
Imaging of the dopaminergic pathway seems to be the only, reasonably available, technique to aid the
differential diagnosis between drug-induced parkinsonism and Parkinson's disease.
© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).urologiche e del Movimento,
Verona, Italy. Tel.: þ39 (0)
rigo).
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Ltd. This is an open access article u1. Introduction
Drug-induced parkinsonism (DIP) has been deemed the most
prevalent form of secondary parkinsonism in the Western world
and the second most common cause of parkinsonism after
idiopathic Parkinson's disease (PD) [1]. DIP was initiallynder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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recognized as possible side effect of a number of other com-
pounds including antiemetics, cholinomimetics, antidepressants,
anti-vertigo medications, calcium channel antagonists, antiar-
rhythmics, and antiepileptic drugs [2]. The raising prevalence of
DIP is likely due to the increasing life expectance of the popu-
lation, since there is an age-related attrition of nigrostriatal
dopamine neurons [3]. Moreover, as people age, they are more
frequently subjected to polypharmacotherapy, particularly for
behavior-related disorders, which are relatively common among
the elderly.
Although being very frequent, there are no widely accepted
diagnostic criteria for DIP. The latter is presumed when a parkin-
sonian syndrome develops during treatment with a potential
offending medication (usually a dopamine receptor blocking drug)
[1]. Symptoms should recover within 6 months of withdrawal of
drug treatment, if applicable [4]. However, the exposure to an
offending drug can not be taken alone as the ﬁnal proof to make a
diagnosis of DIP, since symptoms, in a number of cases, do not
improve or even worsen after that the “offending” drug has been
withdrawn [5], raising the suspicion of the concomitant develop-
ment of PD. A number of clinical clues have been highlighted to aid
the differential diagnosis between DIP and PD, and these include
symmetry of symptoms, relative absence of rest tremor, coexis-
tence of oro-mandibular dyskinesias and a less pronounced, if any,
response to the levodopa [6]. However, DIP can be clinically
indistinguishable from PD in a number of patients [6e9].
A few studies have been recently conducted to assess
whether certain non-motor symptoms (NMS) or ancillary in-
vestigations, including dopamine transporter imaging, trans-
cranial sonography of the substantia nigra, and 123I-meta-
iodobenzylguanidine (MIBG) cardiac scintigraphy, can help the
differential diagnosis between these two conditions. Proper
distinction between DIP and PD has obviously crucial conse-
quences, with regard of both management and long-term
prognosis of these patients. We therefore aimed here to re-
view such studies in order to ascertain whether there is enough
evidence for any of these techniques or for the assessment of
NMS to be recommended in clinical practice to aid the differ-
ential diagnosis between DIP and PD.
2. Methods
The electronic database MEDLINE (accessed by Pubmed; 10th January
2004e10th January 2014) was searched using the free term “drug-induced
parkinsonism” to ﬁnd relevant articles. No language restrictions were applied.
All the titles and abstracts of publications identiﬁed by the search were eval-
uated for their eligibility. We excluded studies conducted in animals, case re-
ports, letters, editorials, and narrative reviews. Studies reporting data on non-
motor symptoms (NMS) or ancillary investigations potentially helpful in the
differential diagnosis between these PD and DIP were considered eligible and,
therefore, those focusing only on motor symptoms of DIP have been excluded.
We excluded publications that did not meet preliminary criteria at this stage.
Following screening, we assessed the full-text of potentially eligible citations for
inclusion.
3. Results
3.1. Non-motor symptoms
Patients with PD commonly manifest NMS since the earliest
stage of disease [10] and some NMS such as hyposmia and sleep
disturbances can also predate the motor onset in PD [11]. NMS
likely reﬂect involvement of both dopaminergic and non-
dopaminergic systems in PD [12] and this, theoretically, is not to
be expected in DIP.
Kim and colleagues have recently evaluated presence of NMS in
28 patients with DIP, 35 drug-naïve patients with PD, and 32healthy controls, using the Non Motor Symptoms Scale (NMSS).
They found that the NMSS total score was higher in PD patients
than in subjects with DIP and healthy controls. Moreover, after
having controlled for age and gender, such NMS as urinary and
sleep disturbances, attention deﬁcit, and hyposmia were found to
be signiﬁcantly associated with PD [13]. The notion that hyposmia
can accurately discriminate between PD and DIP patients, has been
further conﬁrmed by others [14e16]. Using the Snifﬁn' Sticks test
(SST) in 16 DIP patients, 13 PD patients and 19 healthy controls, Bovi
et al. found that DIP patients (with normal dopaminergic imaging
as assessed by means of [(123)I] FP-CIT SPECT e DaT-Scan) had
smell function similar to healthy controls. On the other hand, a sub-
group of patients with DIP had impaired smell function and this
predicted an abnormal dopaminergic imaging, suggesting that
these patients had eventually developed degenerative PD [15].
Similar results were found by Morley et al.: hyposmia was signiﬁ-
cantly more common among subjects with PD than in those with
DIP, and olfactory testing correctly predicted whether subjects
would have recovered after drug withdrawal in 11/13 cases (un-
published data) [16]. Lee and colleagues further provided support
to the value of smell function assessment in the differential diag-
nosis between DIP and PD (the results of this study are detailed
below, see cardiac MIBG scintigraphy section) [14]. Conversely,
Kruger and colleagues have reported that among 59 depressed
patients treated with antipsychotic drugs, 15 developed DIP and
had worse smell function (assessed by mean of SST) than patients
who did not develop DIP [17]. However, there are a few aspects
including absence of control groups of PD patients and/or healthy
subjects, the cross-sectional study design with no follow-up, and
lack of imaging techniques to exclude pre-clinical PD unmasked by
the offending drug, which greatly limit the results of this study.
Other studies have focused on cognition in DIP. When compared
to schizophrenic patients without DIP, those with DIP complain
more frequently about cognitive disturbances [18]. Severity of DIP
has been also found to correlate with the severity of subjective
cognitive complaints [19], suggesting that cognitive issues can be
directly linked to the DIP rather than to the treatment or to the
associated psychiatric condition. A subsequent study tried there-
fore to address the characteristics of the cognitive impairment
associated with DIP [20]. An extensive neuropsychological battery
assessing memory, attention/executive, visuospatial, and language
functions, was administered to 91 patients with PD, 13 patients
with DIP and 22 healthy controls. Although cognitive function in
DIP patients was signiﬁcantly worse than in control in several do-
mains, no signiﬁcant differences were found with PD patients,
apart from the copy of the Rey complex ﬁgure and the contrasting
program. No other tests were performed to assess whether visuo-
spatial functions can accurately discriminate between DIP and PD
patients, whereas other tests assessing frontal functions failed to
conﬁrm the trend observed with the contrasting program. These
ﬁndings suggest that cognitive impairment is common among DIP
patients, but that there is no clear cognitive pattern, which can aid
the differential diagnosis between DIP and PD.
A summary of the aforementioned studies is provided in Table 1.
Overall, a few evidence supports smell function assessment to aid
the differential diagnosis between DIP and PD. Moreover, there are
preliminary suggestions highlighting that such NMS as urinary and
sleep symptoms are suggestive of PD rather of DIP, but further
studies with objective measurements of urinary and sleep impair-
ment arewarranted to clarify their role in the differential diagnosis.
3.2. Transcranial sonography of the substantia nigra
Transcranial sonography (TS) of the substantia nigra has been
recently proposed as a useful technique in the diagnosis of
Table 1
Clinical studies assessing non-motor symptoms.
Study Type of NMS
assessed
Population Method Main ﬁndings
Kim et al., 2013 Several NMS 35 drug-naïve PD in the early
stages, 28 DIP, 32 healthy controls
Non motor symptoms scale (NMSS) The total NMSS score was higher in
PD than in DIP patients.
Urinary symptoms, sleep disturbances,
attention deﬁcit, and hyposmia were
signiﬁcantly associated with PD.
Lee et al., 2007 Olfactory
impairment
24 PD, 15 DIP, 15 healthy controls Cross cultural smell identiﬁcation (CSSI)
test and cardiac 123I-MIBG scintigraphy
Smell function was impaired in PD
patients but not in those with DIP.
No difference between DIP patients
and healthy controls.
Bovi et al., 2010 Olfactory
impairment
13 PD, 16 DIP, 19 healthy controls “Snifﬁn'Sticks” test and [(123)I]
FP-CIT SPECT
Patients with DIP and pathological
putamen uptake had abnormal
olfactory function. DIP patients
with normal putamen uptake
showed smell functions similar
to control subjects.
Morley et al., 2013 Olfactory
impairment
13 DIP Not explicitly reported Hyposmia was signiﬁcantly more
common among PD patients compared
with DIP, and olfactory testing correctly
predicted whether subjects would
recover after drug withdrawal in 11/13
cases (unpublished data).
Kruger et al., 2008 Olfactory
impairment
59 depressed patients treated
with antipsychotic drugs
(15 patients with DIP)
“Snifﬁn' Sticks” test Olfaction was found to be worse in
DIP patients when compared to those
who did not develop DIP
Kim et al., 2008 Cognition 58 Schizophrenic patients
with (34)/without (24) DIP
Frankfurt complaint questionnaire Patients with DIP had more cognitive
complaints
Kim et al., 2009 Cognition 91 Patients with schizophrenia
(61 with/30 without DIP)
Frankfurt complaint questionnaire Severity of DIP signiﬁcantly correlated
with the total score of the questionnaire.
Kim et al., 2011 Cognition 91 PD, 13 DIP, 22 healthy controls Neuropsychological tests assessing memory,
attention/executive, visuo-spatial, and
language functions
No signiﬁcant differences between DIP
and PD patients.
DIP: drug-induced parkinsonism; NMS: non-motor symptoms; PD: idiopathic Parkinson's disease; SPECT: single photon emission computed tomography.
F. Brigo et al. / Parkinsonism and Related Disorders 20 (2014) 808e814810parkinsonian syndromes [21]. In PD, an enlarged area of echoge-
nicity in the substantia nigra, which is thought to be associated
with increased iron concentrations, is observed in more of 90% of
patients and might allow an early differential diagnosis [21].
In one prospective study, diagnostic accuracy of substantia nigra
TS was assessed in 196 patients with clinically undetermined
parkinsonism of recent onset [22]. A clinical re-evaluation after 2
years served as a surrogate gold standard and 7 subjects (3.6%)
were eventually diagnosed with DIP. Hyperechogenicity of the
substantia nigra had overall low sensitivity and speciﬁcity values
for the diagnosis of PD (40%, CI: 30e50%; and 61%, CI: 52e70%,
respectively) and therefore for its differentiation from secondary
parkinsonisms such as DIP.
A further prospective study used substantia nigra TS to specif-
ically evaluate 20 patients with suspected DIP [23]. These patients
were clinically re-assessed after a minimum time of 6 months after
discontinuation of the anti-dopaminergic drug and classiﬁed as
affected by DIP if parkinsonism had resolved or, alternatively, as
subclinical drug-exacerbated parkinsonism if symptoms persisted/
worsened thereafter. No statistically signiﬁcant differences as to the
hyperechogenicity in the substantia nigra or in the lentiform nu-
cleus were found between the two groups. Combined assessment
of TS alterations in both structures had a negative predictive value
of 85.7% for diagnosis of DIP, with a negative likelihood ratio of 0.3.
Details of such studied are provided in Table 2. Overall, there is
not yet enough evidence to support the use of TS of the substantia
nigra for the differential diagnosis between DIP and PD.
3.3. Dopamine transporter imaging
SPECT using (123) I-ioﬂupane (FP-CIT) as dopamine transporter
ligand (DaT-Scan) is the only approved technique to differentiatePD form other tremulous disorders [24]. The formal indications for
the DaT-scan, however, do not cover the differential diagnosis be-
tween PD and symptomatic parkinsonisms (including DIP) [24] and
therefore its role in such cases remains controversial.
A body of evidence has been produced suggesting that the DaT-
Scan can be a reliable technique to differentiate between PD and
DIP patients with relatively good sensitivity and speciﬁcity values
[25e27]. On the other hand, several studies have also shown that a
number of DIP patients can show an abnormal DaT-Scan. Such sub-
group has been deemed to reﬂect sub-clinical PD unmasked by the
anti-dopaminergic drugs rather than true DIP and, in fact, in these
patients motor symptoms do not recover after that the offending
drug has been withdrawn [28e34]. Moreover, this sub-group is
more likely to beneﬁt from levodopa therapy [32,34], further sup-
porting the notion that these patients have PD unmasked by anti-
dopaminergic drugs rather than true DIP due to blockade of post-
synaptic dopaminergic receptors. A further prospective study has
conﬁrmed that, after adjustment for possible confounders,
abnormal DaT-Scan ﬁndings at baseline were the only predictor of
subsequent motor disability progression and better outcome
following levodopa treatment [34].
In summary, there is enough evidence to deem the DaT-Scan as
a useful technique for the differential diagnosis between DIP and
PD (Table 2). Patients treated with anti-dopaminergic drugs who
develop parkinsonism can be in fact classiﬁed into two broad
groups: 1) those in whom parkinsonian symptoms are only due to
blockade of post-synaptic dopamine-receptors by an offending
agent, (these patients have normal SPECT ﬁndings and no evidence
of disease progression at follow-up); and 2) those in whom a sub-
clinical nigro-striatal degeneration is unmasked by anti-
dopaminergic treatment and symptoms progress after the offend-
ing drug has been withdrawn. SPECT ﬁndings might also predict
Table 2
Clinical studies assessing transcranial sonography of the substantia nigra, dopamine transporter imaging, and scintigraphy for myocardial sympathetic innervation.
Study Objective Population Method Main ﬁndings
Bouwmans et al., 203 Investigate the diagnostic
accuracy of substantia
nigra TS in
196 Patients with clinically
undetermined parkinsonism
of recent onset (7 patients
eventually diagnosed with DIP)
Substantia nigra TS Low sensitivity (40%, CI 30e50%) and speciﬁcity
(61%, CI 52e70%) for PD
Substantia nigra TS is not enough accurate to
differentiate PD from other parkinsonian
syndromes such as DIP
Olivares Romero et al., 2013 Investigate substantia
nigra TS ﬁndings in DIP patients
20 PD, 20 possible DIP (15
eventually diagnosed with
deﬁnite DIP, 5 eventually diagnosed
with subclinical drug-exacerbated
parkinsonism)
Substantia nigra and
lentiform nucleus TS
Combined assessment of TS alterations in
both substantia nigra and lentiform nucleus
had a negative predictive value of 85.7% for
diagnosis of deﬁnite DIP, with a negative
likelihood ratio of 0.3
Vlaar et al., 2008 Investigate the diagnostic
accuracy of I-123-FP-CIT
SPECT in differentiating
between PD and DIP
248 patients with parkinsonism I-123-FP-CIT SPECT Mean odds ratio to distinguish between
PD and DIP of 36 (95% CI 2e296)
Diaz-Corrales et al., 2010 Investigate the diagnostic
accuracy of I-123-FP-CIT
SPECT in differentiating between
PD with/without antidopaminergic
treatment and DIP
25 PD unmasked by antidopaminergic
drugs, 22 PD without a previous
antidopaminergic treatment, 32 DIP
I-123-FP-CIT SPECT Normal results in 29 (90.6%) patients
with DIP and abnormal in all patients
with PD (qualitative assessments of
SPECT images).
Cuberas-Borros et al., 2011 Investigate the diagnostic
accuracy of I-123-FP-CIT SPECT in
differentiating between PD, DIP,
and essential tremor
20 PD, 20 DIP, 20, essential tremor I-123-FP-CIT SPECT Uptake decrease in the putamen nuclei
was found only in PD
Olivares Romero et al., 2013 Investigate the diagnostic accuracy
of I-123-FP-CIT SPECT in differentiating
between iatrogenic parkinsonism and
subclinical drug-exacerbated parkinsonism
19 DIP evaluated at least 6 months
after discontinuation of antidopaminergic
drugs
I-123-FP-CIT SPECT Sensitivity of 66.7%, speciﬁcity and
positive predictive value of 100%,
negative predictive value of 86.7%,
and a negative likelihood ratio of 0.33
for diagnosis of iatrogenic parkinsonism
or subclinical drug-exacerbated parkinsonism.
Tinazzi et al., 2008 To investigate the status of dopamine
nerve terminals in DIP patients following
antidopaminergic therapy
32 DIP, 26 healthy controls I-123-FP-CIT SPECT SPECT binding was reduced in 14 patients
(PD unmasked by the anti-dopaminergic
medication) and normal in 18 patients.
Symmetry of parkinsonism and
bucco-linguo-masticatory dyskinesias
more frequent in patients with normal
tracer binding.
Tinazzi et al., 2009 To investigate the status of dopamine
nerve terminals in DIP patients following
antidopaminergic therapy
10 DIP with normal I-123-FP-CIT SPECT
binding (group 1), 9 DIP with abnormal
I-123-FP-CIT SPECT binding (group 2).
I-123-FP-CIT SPECT
performed at 19e39-month
follow-up
At follow-up, SPECT was still normal and
UPDRS motor score values did not progress
in all patients of the group 1. Conversely,
both putaminal dopaminergic denervation
on the scan and UPDRS motor scores
progressed at follow up in group 2.
Levodopa treatment improved motor
symptoms in 30% of the patients in
group 1 and in 88.9% of patients in group 2.
Tinazzi et al., 2012 To estimate the prevalence of DIP and,
among patients with DIP, the prevalence
of I-123-FP-CIT SPECT abnormalities in
schizophrenic patients.
448 Schizophrenic patients treated with
antipsychotics for at least 6 months
I-123-FP-CIT SPECT DIP was identiﬁed in 149 out of 448
patients (33%). Neuroimaging abnormalities
were found in 41 of 97 DIP patients who
underwent SPECT (42%). The latter group
was deemed to have PD unmasked by the
offending drug.
Tinazzi et al., 2013 To investigate the status of dopamine
nerve terminals in DIP patients
60 patients with schizophrenia and
parkinsonism with I-123-FP-CIT SPECT
at baseline evaluation (normal SPECT ¼ 33;
abnormal SPECT ¼ 27)
I-123-FP-CIT SPECT performed
at 2-years follow-up
Patients with baseline abnormal SPECT
had higher UPDRS motor scores at follow-up
and were more likely to respond to levodopa
treatment.
(continued on next page)
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Table 2 (continued )
Study Objective Population Method Main ﬁndings
Abnormal SPECT ﬁndings at baseline were
the only predictor of motor disability
progression and of better outcome
following levodopa treatment
Lee et al., 2006 Investigate the role of 123I-MIBG
scintigraphy in differentiating between
DIP and PD
20 patients with DIP, 32 with PD,
20 healthy controls
123I-MIBG Scintigraphy The mean heart to mediastinum ratio was
signiﬁcantly greater in patients with DIP
than in those with PD; MIBG uptake was
not different between the DIP patients and
controls; two DIP patients whose MIBG
uptake was reduced showed persistent
parkinsonism with a dramatic response
to levodopa
Lee et al., 2007 Investigate olfactory function and its
relation to cardiac 123I-MIBG uptake in
patients with DIP
15 patients with DIP, 24 patients with
PD and 15 healthy controls
Mean cross cultural smell
identiﬁcation odour test
(CCSI) score; 123I-MIBG
scintigraphy
Smell function was found to be normal
in 93% of patients with DIP, and all DIP
patients with a normal CCSI score had
also normal cardiac MIBG uptake. One
DIP patient whose CCSI score was signiﬁcantly
reduced also had decreased cardiac MIBG uptake
Kim et al., 2012 Diagnostic accuracy of combined use of
123I-MIBG scintigraphy and FP-CIT PET in
distinguishing the prognosis in DIP patients
20 patients with DIP followed for more
than 2 years after withdrawal of offending
drug
FP-CIT SPET and 123I-MIBG
scintigraphy; clinical valutation
of parkinsonism at the beginning
of the study and 3,6,12,18 and
24 months after withdrawal
of the offending drug
DAT uptake and MIBG uptake were found
to be normal in 16 of 20 patients with DIP,
and all these patients had a clinical remission of
parkinsonian motor symptoms within 3 months
after withdrawal of offending drug; two patients
with a decrease in DAT and MIBG uptake showed
persistent motor symptoms after withdrawal
of offending drug; other 2 patients with a
normal DAT uptake and decreased MIBG
uptake showed remission of motor symptoms
after withdrawal of the offending drug within
2 months, with reappearance of parkinsonian
syndrome during the follow-up period.
DIP: drug-induced parkinsonism; PD: idiopathic Parkinson's disease; SPECT: single photon emission computed tomography; TS: transcranial sonography.
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the prognosis of these patients.
3.4. Cardiac 123I-MIBG scintigraphy
Several studies have shown that cardiac MIBG uptake is signif-
icantly reduced in patients with PD [35] compared to healthy
controls; furthermore, it has been claimed that this technique
might help differentiating PD from other forms of degenerative
parkinsonism [36]. Conversely, only a few studies have assessed the
role of cardiac MIBG scintigraphy in the differential diagnosis be-
tween PD and DIP (Table 2).
Lee et al. studied 20 patients with DIP cardiac MIBG scintig-
raphy. In up to 90% of these patients, MIBG uptake was found to be
normal. The remaining two patients, who disclosed an abnormal
MIBG uptake, manifested persistent parkinsonism after the with-
drawal of the offending drug, and a dramatic response to levodopa
treatment. This scenario bears resemblance to what has been dis-
cussed above for the DaT-Scan and highlights the fact that a
number of patients can have sub-clinical PD unmasked by anti-
dopaminergic treatments [37]. The same research group has also
evaluated the relationship between smell function and cardiac
123I-MIBG scintigraphy in 15 DIP patients, 24 PD patients, and 15
healthy controls [37]. Smell function was found to be normal in all
DIP patients with normal MIBG cardiac uptake, whereas one pa-
tient (1/15, 6.7%) with an impaired smell function had also
decreased cardiac MIBG uptake and persistence of motor symp-
toms after withdrawal of the offending drugs, suggesting that such
patient had eventually developed degenerative PD.
Interestingly, a prospective 2-year follow-up study using both
[18F] FP-CIT PET and cardiac MIBG scintigraphy in DIP patients has
suggested the latter to early predict subsequent development of
degenerative parkinsonism [13]. Out of 20 patients, 16 showed
normal DAT binding and normal myocardial sympathetic innerva-
tion and their parkinsonism resolved within 3 months after the
withdrawal of the offending drug. Two patients showed instead
both decreased dopamine transporter binding and impaired car-
diac sympathetic innervation, and clinically worsened at follow-up,
thus being deemed to have PD unmasked by anti-dopaminergic
drugs. The remaining two patients had normal or very marginal
reduction of DAT binding and clearly decreasedMIBG uptake. These
two patients fully recovered within 2 months after the drug
discontinuation, but eventually developed PD within the following
2 years. A second scan showed clear decreased dopamine trans-
porter binding, suggesting a possible role of sympathetic cardiac
denervation as a very early marker of PD, as previously suggested
[38].
All these studies suggest that MIBG cardiac scintigraphy might
be a promising technique to aid the differential diagnosis between
DIP and PD. Further studies with larger samples are needed in this
regard.
4. Conclusions
Clinical differentiation between DIP and PD can be challenging
in the early stage of the disease. Proper distinction between DIP and
PD patients has crucial implications in terms of management and
prognosis. This is mainly based on the assumption that DIP is a non-
degenerative condition, which should resolve after discontinuation
of the causative agent, if applicable. However, a body of evidence
has been produced that a number of patients have actually sub-
clinical neurodegenerative parkinsonism unmasked by the
offending drug. In such cases, distinction of these patients is even
more challenging based on the clinical assessment of motor
features.There is preliminary evidence that some NMS such urinary and
sleep disturbances, might point towards a PD diagnosis, but studies
addressing this topic had a number of limitations including small
samples size and cross-sectional design. More robust evidence
exists for hyposmia, which seems to accurately differentiate be-
tween patients with “pure” DIP and those with degenerative PD
unmasked by an offending drug. Smell function assessment is a
easy, cheap and quick tool that can be routinely used in clinical
practice. However, it should be also noted that smoking history,
concomitant otorhinolaryngoiatric diseases, attention and cogni-
tive status inﬂuence smell function assessment.
Higher diagnostic accuracy can be obtained by mean of dopa-
mine transporter imaging which has been shown to reliably
differentiate between patients with pure DIP and patients who
have a subclinical PD unmasked by an anti-dopaminergic drug.
Abnormal dopamine transporter imaging seems also to predict a
good response to levodopa therapy in the latter group. Interest-
ingly, it has been reported that an abnormal MIBG cardiac scintig-
raphy might predate dopamine transporter imaging abnormalities
and accurately differentiate between DIP and PD patients, but
further prospective long-term follow-up studies are needed to
conﬁrm this suggestion. No enough evidence exists for the TS of the
substantia nigra in the differential diagnosis between DIP and PD.
Overall, dopamine transporter imaging seems to be the only,
reasonably available, technique to aid the differential diagnosis
between DIP and PD, although there is no speciﬁc mention in this
regard in the current formal indications for the dopamine trans-
porter imaging. Further studies are warranted to see whether some
of the techniques reviewed here can be advised in the clinical
practice when facing a patient supposed to be affected with DIP.
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